Mount Sinai Researchers Identify New Therapeutic Target for Cancer
New research from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therapies. The protein, known as kinase suppressor of Ras, or KSR, is a pseudoenzyme that plays a critical role in the transmission of signals in the cell determining whether cells grow, divide, or die. The findings, published in the September issue of the journal Nature, show that targeting KSR could have important therapeutic implications, potentially improving outcomes in many aggressing cancers such as lung and pancreatic cancer.
Ras is the most frequently mutated human cancer gene (oncogene), yet despite recent breakthroughs, therapeutic options to target Ras-dependent cancers remain limited. Previous studies had supported the possibility of targeting oncogenic forms of Ras via KSR, but no pharmacological approaches had been reported until now.
“New drug targets for Ras-dependent cancers have long been sought,” said Arvin Dar, PhD, Assistant Professor of Oncological Sciences and Pharmacological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and lead researcher on the study. “We used data on known genetic variants in KSR that suppress mutant Ras signaling to guide the development of novel compounds. In this way our study took a very different approach as we have used chemistry to mimic genetic mechanisms that are able to block the development of Ras-dependent cancers.”
The lead compound reported in the study, APS-2-79, was shown to modulate Ras signaling and increased the potency of several other cancer drugs within RAS-mutant cell lines. “KSR belongs to a large class of proteins that are not only implicated in the development of cancer, but also other diseases as well,” Dr. Dar explained. “No one has really figured out how to exploit these important drug targets. Our study opens the possibility of modulating KSR as a new cancer therapy and also potentially an entirely new class of interventions.”
The co-first authors of the paper are Neil Dhawan and Alex Scopton, graduate student and postdoctoral fellow, respectively, in the Dar laboratory. The work was supported by grants from the National Institutes of Health, the Damon Runyon-Rachleff Foundation, the Pew-Stewart Foundation, and the Pershing Square Sohn Cancer Research Alliance.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.